1374996-60-7

Basic information

• Product Name: 6H-INDENO[1,2-E]TETRAZOLO[1,5-B][1,2,4]TRIAZIN-6-ONE
• Synonyms: ZERENEX E/6026591;6H-INDENO[1,2-E]TETRAZOLO[1,5-B][1,2,4]TRIAZIN-6-ONE;10H-Indeno[2,1-e]tetrazolo[1,5-b][1,2,4]triazin-10-one (1:1)
• CAS NO: 1374996-60-7
• Molecular Formula: C10H4N6O
• Molecular Weight: 224.18
• Mol File: 1374996-60-7.mol
• Article Data: 0

Chemical Properties

• Appearance: light yellow to dark yellow/
• Storage Temp.: 2-8°C
• Solubility: DMSO: soluble10mg/mL, clear
• CAS DataBase Reference: 6H-INDENO[1,2-E]TETRAZOLO[1,5-B][1,2,4]TRIAZIN-6-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6H-INDENO[1,2-E]TETRAZOLO[1,5-B][1,2,4]TRIAZIN-6-ONE(1374996-60-7)
• EPA Substance Registry System: 6H-INDENO[1,2-E]TETRAZOLO[1,5-B][1,2,4]TRIAZIN-6-ONE(1374996-60-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 1374996-60-7(Hazardous Substances Data)

Usage

Description

6H-Indeno[1,2-e]tetrazolo[1,5-b][1,2,4]triazin-6-one is a complex heterocyclic compound characterized by its unique chemical structure, which consists of a fused ring system containing both tetrazolo and triazinone moieties. This molecule exhibits a high level of structural complexity and has the potential for various applications in different fields due to its diverse chemical properties.

Uses

Used in Pharmaceutical Industry:
6H-Indeno[1,2-e]tetrazolo[1,5-b][1,2,4]triazin-6-one is used as a pharmaceutical compound for its potential therapeutic applications. The complex structure of this molecule allows it to interact with various biological targets, making it a promising candidate for the development of new drugs.
Used in Chemical Research:
In the field of chemical research, 6H-Indeno[1,2-e]tetrazolo[1,5-b][1,2,4]triazin-6-one serves as a valuable compound for studying the properties and reactivity of heterocyclic systems. Its unique structure can provide insights into the design and synthesis of novel molecules with specific chemical and biological activities.
Used in Material Science:
6H-Indeno[1,2-e]tetrazolo[1,5-b][1,2,4]triazin-6-one can be utilized in material science as a component in the development of new materials with tailored properties. Its heterocyclic structure may contribute to the creation of materials with enhanced stability, conductivity, or other desirable characteristics.
Used in Cancer Treatment:
6H-Indeno[1,2-e]tetrazolo[1,5-b][1,2,4]triazin-6-one is used as an anticancer agent, targeting various types of cancer cells. Its complex structure allows it to modulate multiple signaling pathways involved in cancer cell proliferation and survival, potentially leading to the development of new therapeutic strategies against cancer.
Used in Drug Delivery Systems:
To improve the bioavailability and therapeutic efficacy of 6H-Indeno[1,2-e]tetrazolo[1,5-b][1,2,4]triazin-6-one, it can be incorporated into drug delivery systems. These systems can enhance the compound's delivery to target tissues, reduce side effects, and improve its overall performance in treating various diseases, including cancer.

in vitro

a previous study found that kp372-1 could block signalling downstream of akt in thyroid tumour cells, resulting in inhibition of cell proliferation and increased apoptosis [1]. another study showed that kp372-1 directly inhibited the kinase activity of akt, flt3, and pdk1concentration-dependently. western blot analyses indicated kp372-1 decreased the phosphorylation of akt on both ser(473) and thr(308). moreover, the treatment of aml cell lines with kp372-1 led to rapid generation of reactive oxygen species and stimulation of oxygen consumption. in addition, kp372-1 was able to induce pronounced apoptosis in aml cell lines and primary samples irrespective of their flt3 status, but not in normal cd34(+) cells [2].

IC 50

30-60 nm for thyroid cancer cells

references

[1] mandal, m. ,kim, s.,younes, m.n., et al. the akt inhibitor kp372-1 suppresses akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. british journal of cancer 92(10), 1899-1905 (2005).[2] zeng, z. ,samudio, i.j.,zhang, w., et al. simultaneous inhibition of pdk1/akt and fms-like tyrosine kinase 3 signaling by a small-molecule kp372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. cancer research 66(7), 3737-3746 (2006).